Batu Biologics Recruits Vice President of Precision Oncology

Batu Biologics Recruits Dr. Vijay Mahant as the Vice President of Precision Oncology to Oversee the Personalization of ValloVax Immunogenicity

Dr. Mahant to assist with the development of screening criteria to identify patients who are most likely to receive clinical benefit from the ValloVax immunotherapy

Today, Batu Biologics announced the recruitment of Dr. Vijay Mahant to the management team in the position of Vice President of Precision Oncology. Under this role, Dr. Mahant will assist with the optimization of the clinical development of ValloVax, with a focus on identifying methods to stratify patients based on biomarkers that may be able to predict response to therapy.

Read the full article at businesswire.com

Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog

Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog

Clinical Stage Immuno-Oncology Company Releases Media Platform to Provide Background Information on Lead Technology

Today, Batu Biologics announced the release of the Starve The Tumor Video Blog, a series of informational videos and articles designed to provide background information on our lead therapeutic ValloVax. Batu Biologics’ lead clinical candidate, ValloVax, is a first-in-class placenta derived endothelial cell based vaccine designed to stimulate an immune response against several tumor angiogenesis associated antigens for the treatment of solid tumor carcinomas.

Read the full article at businesswire.com

Batu Biologics Identifies Gene Types Associated with Response to ValloVax

Batu Biologics Identifies Gene Types Associated with Response to ValloVax

Preliminary Evaluation of Over 100 Patients Treated with Cancer Blood Vessel Targeting Immunotherapy Reveals Gene Association with Clinical Response

Batu Biologics announced today filing of a patent covering methods of matching cancer patients with experimental drugs under the new Right to Try Law. The recently passed law allows for companies that have passed Phase I of clinical trial to start offering terminal patients access to drugs that are still in development.

Read the full article at businesswire.com

Batu Biologics files Right to Try Patent

Batu Biologics Files Patent on Patient Selection for Right to Try Law

Clinical Stage Immunotherapy Company Creates System of Selecting Patients for Optimized Outcome under President Donald Trump’s Right to Try Law

Batu Biologics announced today filing of a patent covering methods of matching cancer patients with experimental drugs under the new Right to Try Law. The recently passed law allows for companies that have passed Phase I of clinical trial to start offering terminal patients access to drugs that are still in development.

Read the full article at businesswire.com

Batu Biologics Recruits Nobel Prize Winner Bruce Beutler

Nobel Prize Winning Immunologist Joins Batu Biologics in Quest to “Starve the Tumor”

Clinical Stage Immuno-Oncology Company Recruits Pioneer of Innate Immunity to Scientific Advisory Board

Batu Biologics announced today the appointment of Nobel Prize winner Dr. Bruce Beutler to the Company’s Scientific Advisory Board.

Read the full article at businesswire.com

Batu Biologics Raises $1.3 Million in Equity Crowdfunding

Batu Biologics Successfully Completes $1.3 Million #Starvethetumor Equity Crowdfunding Campaign

Company Intends to Aggressively Pursue Clinical Development of Angiogenesis Targeting Immunotherapy Product ValloVax

Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announced today the successful closure of a regulation 506(c) equity crowdfunding offering bringing in $1.3 Million in capital to the Company.

Read the full article at businesswire.com

Batu Biologics Recruits Dr. Vijay Mahant to SAB

Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm

Vijay Mahant, PhD, will lead efforts in the development of gene-guided precision medicine related to the ValloVax immune therapy

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Vijay Mahant, PhD, to its Scientific Advisory Board.

Read the full article at businesswire.com

Batu Biologics selected to present at Cavendish Global Forum

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

Batu Biologics, an immuno-oncology company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida.

Read the full article at businesswire.com

Dr. Thomas Ichim joins as full-time CSO

Founder of Batu Biologics Expands Involvement as Chief Scientific Officer

Thomas Ichim, PhD, will oversee the scientific development of the ValloVax therapeutic program

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Thomas Ichim, PhD, to the position of Chief Scientific Officer.

Read the full article at businesswire.com